The 10-second takeaway
For the quarter ended Dec. 31 (Q4), Thoratec beat slightly on revenues and beat expectations on earnings per share.
Compared to the prior-year quarter, revenue expanded and GAAP earnings per share improved significantly.
Gross margins expanded, operating margins were steady, net margins expanded.
Thoratec logged revenue of $109.4 million. The 20 analysts polled by S&P Capital IQ predicted a top line of $107.4 million. GAAP sales were 12% higher than the prior-year quarter's $97.6 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Non-GAAP EPS came in at $0.38. The 19 earnings estimates compiled by S&P Capital IQ forecast $0.33 per share on the same basis. GAAP EPS of $0.25 for Q4 were 19% higher than the prior-year quarter's $0.21 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 67.1%, 80 basis points better than the prior-year quarter. Operating margin was 22.9%, about the same as the prior-year quarter. Net margin was 14.0%, 110 basis points better than the prior-year quarter.
Next quarter's average estimate for revenue is $110.9 million. On the bottom line, the average EPS estimate is $0.39.
Next year's average estimate for revenue is $458.2 million. The average EPS estimate is $1.64.
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 147 members out of 168 rating the stock outperform, and 21 members rating it underperform. Among 48 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 42 give Thoratec a green thumbs-up, and six give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Thoratec is outperform, with an average price target of $35.71.
Over the decades, small-cap stocks, like Thoratec have provided market-beating returns, provided they're value priced and have solid businesses. Read about a pair of companies with a lock on their markets in "Too Small to Fail: Two Small Caps the Government Won't Let Go Broke." Click here for instant access to this free report.
- Add Thoratec to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.